Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Skin, Hair and Nails

Skin, Hair and Nails

Recruiting

Preventing skin cancer with nicotinamide in transplant patients

The purpose of this study is to determine whether an oral vitamin called nicotinamide can help prevent skin cancer in 396 high-risk kidney, liver, heart and lung transplant recipients. Participants will be involved in the study for four years and will visit the study doctor or clinical research staff every 17 weeks. Participants will receive nicotinamide or a placebo, taken orally for the entire follow-up period, which will last up to 208 weeks.

Status
Recruiting
Principal Investigator
Sunil Kalia
Body Locations and Systems
Kidneys and Urinary System
Skin, Hair and Nails
Age
18 and above

Investigating the efficacy and safety of brepocitinib in adults with dermatomyositis

The purpose of this study is to assess the efficacy of two dose levels of brepocitinib in adults with dermatomyositis compared to a placebo. After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52-week, open-label extension phase where all participants will receive brepocitinib.

Status
Recruiting
Body Locations and Systems
Bones, Joints and Muscles
Immune System
Skin, Hair and Nails
Age
18-75

Cyclic P4/Spironolactone in PCOS

The purpose of the study is to learn about the impacts of Cyclic Progesterone and Spironolactone on the menstrual cycles, luteinizing hormone and testosterone levels, and quality of life experiences of women living with polycystic ovary syndrome (PCOS).

Recruitment Poster

Status
Recruiting
Principal Investigator
Jerilynn C. Prior
Body Locations and Systems
Endocrine System
Skin, Hair and Nails
Age
19-35

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.

Status
Recruiting
Principal Investigator
Sunil Kalia
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

The purpose of this study is to evaluate the safety and efficacy of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.

Status
Recruiting
Principal Investigator
David Zloty
Body Locations and Systems
Skin Conditions
Area
Vancouver
Age
18 and above

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

The purpose of this study is to evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis who have had an inadequate response to their current biologic agent regimen.

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis

The  purpose of this study is to understand the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in a psoriasis study involving BMS-986165. 

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

 

This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. 

 

 

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Dermatitis
Area
Vancouver
Age
18-70

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.

Status
Recruiting
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury (RE-ENERGIZE)

The purpose of this study is to test the following hypotheses:

Status
Recruiting
Principal Investigator
William Henderson
Body Locations and Systems
Skin Conditions
Area
Vancouver
Age
18 and above

Closed for Recruitment

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

To assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis. To compare the proportion of subjects with moderate to severe psoriasis is experiencing a 75% improvement as measured by reduction in psoriasis area and severity index (PASI-75) score after 12 weeks of treatment between doses of BMS-986165 and placebo.  

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-70

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Status
Closed for Recruitment
Principal Investigator
Jan Dutz
Body Locations and Systems
Shingles
Area
Vancouver
Age
50 and above

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in subjects with unresectable or metastatic melanoma.

Status
Closed for Recruitment
Principal Investigator
Sasha Smiljanic
Body Locations and Systems
Melanoma
Area
North Vancouver
Age
18 and above

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional

The purpose of this study is a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine and will include an assessment of 1 or 2 additional doses in two subgroups of older adults.

Status
Closed for Recruitment
Principal Investigator
Jan Dutz
Body Locations and Systems
Shingles
Area
Vancouver
Age
50 and above

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 24, to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy.

Status
Closed for Recruitment
Principal Investigator
Jan Dutz
Body Locations and Systems
Psoriasis
Psoriatic Arthritis
Area
Vancouver
Age
18 and above

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18-99

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Expanded Access Program With Nivolumab to Treat Melanoma (Checkmate 168)

The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutation, also progressed on or after treatment with a BRAF inhibitor.

Status
Closed for Recruitment
Principal Investigator
Sasha Smiljanic
Body Locations and Systems
Melanoma
Area
Vancouver
Age
18 and above

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity. Efficacy parameters are based on Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and the Pruritus Numerical Rating Scale (NRS).

Status
Closed for Recruitment
Principal Investigator
Vincent Ho
Body Locations and Systems
Dermatitis
Area
Vancouver
Age
18 and above

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Status
Closed for Recruitment
Principal Investigator
Youwen Zhou
Body Locations and Systems
Psoriasis
Area
Vancouver
Age
18 and above

Pagination

  • Current page 1
  • Page 2
  • Next page
Subscribe to Skin, Hair and Nails

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy